Alison is Sionna’s Vice President of Preclinical Safety and has over 20 years of experience in the pharmaceutical industry. She is responsible for preclinical safety studies required to support the Sionna discovery and development portfolios.
Prior to Sionna, Alison spent three years at Praxis Precision Medicines where she supported multiple programs spanning early discovery and late-stage clinical development. She started her career in 2002 at AstraZeneca U.K. as an electrophysiologist within the safety pharmacology group before moving to the U.S. and advancing to a program-focused general discovery toxicology role. This was followed by four years at Biogen where she was a program toxicologist on a variety of small and large molecule programs for CNS and immunology indications.
Alison received her Ph.D. in Molecular Pharmacology from the University of Birmingham, U.K. and is a Diplomate of the American Board of Toxicology.